ALMS trades 49.0% below Wall Street's consensus target of $39.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ALMS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Alumis Inc. Common Stock (ALMS) has a Wall Street consensus price target of $39.33, based on estimates from 8 covering analysts. With the stock currently trading at $26.40, this represents a potential upside of +49.0%. The company has a market capitalization of $3.30B.
Analyst price targets range from a low of $25.00 to a high of $51.00, representing a 66% spread in expectations. The median target of $39.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ALMS trades at a trailing P/E of -9.2x. Analysts expect EPS to grow -50.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ABBVAbbVie Inc. | $444.4B | $251.52 | $258.00 | +2.6% | Buy | 17.7x | 41 |
CLDXCelldex Therapeutics, Inc. | $2.3B | $35.26 | $49.00 | +39.0% | Buy | — | 19 |
ARVNArvinas, Inc. | $516M | $8.00 | $14.75 | +84.4% | Buy | — | 26 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
VTRSViatris Inc. | $19.0B | $16.33 | $17.40 | +6.6% | Hold | 6.6x | 13 |
PFEPfizer Inc. | $138.1B | $24.29 | $26.75 | +10.2% | Hold | 8.2x | 39 |
JNJJohnson & Johnson | $613.0B | $254.66 | $253.42 | -0.5% | Buy | 22.0x | 40 |
BMYBristol-Myers Squibb Company | $117.4B | $57.52 | $62.60 | +8.8% | Hold | 9.1x | 41 |
INCYIncyte Corporation | $22.7B | $113.75 | $108.92 | -4.2% | Buy | 15.2x | 44 |
LGNDLigand Pharmaceuticals Incorporated | $6.1B | $303.59 | $265.33 | -12.6% | Buy | 33.5x | 17 |
Quick answers to the most common questions about buying ALMS stock.
The consensus Wall Street price target for ALMS is $39.33, representing 49.0% upside from the current price of $26.4. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ALMS has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $39.33 implies 49.0% upside from current levels.
ALMS's current price is $26.4 with a consensus target of $39.33 (49.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $51 for ALMS, while the most conservative target is $25. The consensus of $39.33 represents the median expectation. These targets typically reflect 12-month expectations.
ALMS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ALMS stock forecast based on 8 Wall Street analysts shows a consensus price target of $39.33, with estimates ranging from $25 (bear case) to $51 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ALMS, with a "Buy" consensus rating and $39.33 price target (49.0% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ALMS analyst price targets range from $25 to $51, a 66% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.33 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.